Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02120079
Other study ID # 13-150H
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date February 2014
Est. completion date January 28, 2018

Study information

Verified date February 2022
Source Tufts Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This research study is looking to see if in vivo confocal microscopy (IVCM) imaging can be used to confirm clinical findings (which are noted by the doctor during an eye exam) and measure the immune response to the inflammation in the subject's cornea (the front part of the eyeball). Additionally, this study is trying to determine the effectiveness of two eye-drops, Lotemax and artificial tears, in treating the inflammation associated with DED by measuring changes in immune cells with IVCM imaging. The subject will be treated with either Lotemax (loteprednol) or artificial tears (a lubricating eye drop with no medication). Lotemax is an FDA-approved steroid eye-drop that is often used to treat inflammation associated with DED. Artificial tears are approved by the FDA for treatment of dryness associated with DED. Thus, this study is designed to determine the effects of the administration of a topical steroid, Lotemax, over a treatment period of 6 weeks, using novel methods of detecting efficacy. In order to achieve the aforementioned goal, subjects will be prospectively randomized to one of two treatment arms - Lotemax or artificial tear. Both groups will follow the same study schedule.


Description:

IVCM is a non-invasive imaging technique that images the cornea at a cellular level with 800x magnification, using a scanning laser. The laser is used to map the cornea, and will not damage or harm the subject's eye. Studies have shown that IVCM can be used to study cells and nerves within the cornea, providing a better understanding of how the cornea reacts to irritants. IVCM has recently been used by the investigator to assess the extent of eye inflammation in cases of dry eye patients. Current steroid therapy in dry eye disease (DED) is comprised of a 2 week duration of pulse therapy, administered twice daily (to avoid adverse effects associated with long-term steroid use). This time frame is often too short to meaningfully resolve the inflammation associated with DED. DED often occurs when there is a decrease in the eye's tear production or if there is an increase in the evaporation of the tear film (a thin layer of tears that keep the eye moist). Eye irritation and inflammation (swelling) is often associated with DED because the surface of the eye is unable to maintain a normal level of moisture.


Other known NCT identifiers
  • NCT02106377

Recruitment information / eligibility

Status Completed
Enrollment 38
Est. completion date January 28, 2018
Est. primary completion date April 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 89 Years
Eligibility Inclusion Criteria: - Age 18-89 years. - Willing and able to provide written informed consent. - Willing and able to comply with study assessments for the full duration of the study. - In good stable overall health. - Corneal dendritiform cell count by confocal microscopy of >=75/mm2 (13 immune cells per image) - Diagnosis of dry eye disease based on the followings: - Symptoms of dry eye disease such as foreign body sensation, burning, stinging, light sensitivity for at least 6 months. - Two or more of the following objective signs: - Schirmer test with anesthesia <10 mm at 5 minutes [mean Schirmer between eyes. - Tear break-up time (TBUT) of <10 seconds. - Corneal fluorescein staining of 4 (NEI grading scheme, 0-15) in at least one eye - Lissamine green staining of the nasal and temporal conjunctiva (NEI grading scheme, 0-18) in at least one eye Exclusion Criteria: - Central corneal subbasal dendritic cell count by in vivo confocal microscopy of <75/mm2 in both eyes - Active ocular allergies - Active allergies to steroids, aminoglycosides, or benzalkonium chloride (BAK) - History of contact lens wear within 3 months before enrollment. - Intraocular surgery or ocular laser surgery within 3 months before enrollment. - History of ocular infection within 3 months before enrollment. - History of topical (for ophthalmic use) or systemic steroid treatment (Loteprednol (other than Lotemax suspension used in our study), Difluprednate, Fluorometholone, Prednisolone, Dexamethasone, Triamcinolone, Rimexolone, Medrysone) within 1 month before enrollment. In case of topical ophthalmic steroid use, a wash-out period of 1 month is required. - History of increased intraocular pressure after using topical steroids (steroid responsive) - Change in systemic immunosuppression medication in the past 3 months. - History of any change in the frequency of topical cyclosporine or oral tetracycline compounds (tetracycline, doxycycline, and minocycline) within 1 month before enrollment. - Any condition (including language barrier) that precludes subject's ability to comply with study requirements including completion of study.

Study Design


Intervention

Drug:
Lotemax
Lotemax (loteprednol etabonate) 0.5% will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)
Soothe Tired Eyes Lubricant Eye Drop will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
Diagnostic Test:
In Vivo Confocal Microscopy (IVCM)
In vivo confocal microscopy (IVCM) is a new imaging method, which allows visualization of the corneal structures at the cellular level. With a magnification of 800 times, it makes it possible to detect and quantify changes in the epithelial layers and sub-basal nerve plexus.

Locations

Country Name City State
United States Tufts Medical Center Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Tufts Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary IVCM for Density of Corneal Immune Dendritiform Cells Density (in cells/mm2) of Corneal Immune Dendritiform Cells 2 Weeks
Primary IVCM for Density of Corneal Immune Dendritiform Cells Density (in cells/mm2) of corneal immune dendritiform cells 6 Weeks
Primary IVCM for Corneal Immune Dendritiform Cell (DC) Morphology Morphology (in cells/mm2) of Corneal Immune Dendritiform Cells 2 Weeks
Primary IVCM for Corneal Immune Dendritiform Cell (DC) Morphology Morphology (in cells.mm2) of Corneal Immune Dendritiform Cells 6 Weeks
Secondary Ocular Signs: Corneal Epitheliopathy Corneal Fluorescein Staining Using the National Eye Institute (NEI) Grading Scheme Minimum score-0 Maximum score-15 Higher score means worse outcome 2 Weeks
Secondary Ocular Signs: Corneal Epitheliopathy Corneal Fluorescein Staining Using the National Eye Institute (NEI) Grading Scheme Minimum score-0 Maximum score-15 Higher score means worse outcome 6 Weeks
Secondary Ocular Signs: Conjunctival Epitheliopathy Conjunctival Lissamine Green Staining Using National Eye Institute (NEI) Grading Scheme Minimum score-0 Maximum score-18 Higher score means worse outcome 2 Weeks
Secondary Ocular Signs: Conjunctival Epitheliopathy Conjunctival Lissamine Green Staining Using National Eye Institute (NEI) Grading Scheme Minimum score-0 Maximum score-18 Higher score means worse outcome 6 Weeks
Secondary Ocular Symptoms: Ocular Surface Disease Index (OSDI) Questionnaire Total Score of the Ocular Surface Disease Index (OSDI) Questionnaire Minimum score- 0 Maximum score-100 Higher score means worse outcome 2 Weeks
Secondary Ocular Symptoms: Ocular Surface Disease Index (OSDI) Questionnaire Total Score of the Ocular Surface Disease Index (OSDI) Questionnaire Minimum score- 0 Maximum score-100 Higher score means worse outcome 6 Weeks
Secondary Ocular Signs: Intraocular Pressure (IOP) by Measure of Applanation Tonometry Intraocular Pressure (IOP) will be measured via Applanation and the result will have these units: mmHg 2 Weeks
Secondary Ocular Signs: Intraocular Pressure (IOP) by Measure of Applanation Tonometry Intraocular Pressure (IOP) will be measured via Applanation and the result will have these units: mmHg 6 Weeks
Secondary Ocular Signs: Tear Break Up Time (TBUT) Tear Break Up Time (TBUT) will be recorded in seconds 2 Weeks
Secondary Ocular Signs: Tear Break Up Time (TBUT) Tear Break Up Time (TBUT) will be recorded in seconds 6 Weeks
Secondary Ocular Signs: Schirmer's Test With Anesthesia The Schirmer's Test (performed using Anesthesia) will be measured in mm. 2 Weeks
Secondary Ocular Signs: Schirmer's Test With Anesthesia The Schirmer's Test (performed using Anesthesia) will be measured in mm. 6 Weeks
See also
  Status Clinical Trial Phase
Completed NCT03216096 - Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease Phase 1
Completed NCT05825599 - PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms N/A
Completed NCT04656197 - The Ocular Microbiome in Patients With Dry Eye Disease
Completed NCT05031806 - Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease Phase 1
Completed NCT03688802 - Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation Phase 2
Completed NCT05213156 - Concentration of Ofloxacin Into the Aqueous Humour of Patients With Dry Eye Disease Phase 4
Completed NCT04548427 - Study to Evaluate the Efficacy and Safety of CKD-352 Phase 3
Completed NCT06176651 - Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers Phase 4
Completed NCT02254265 - Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca Phase 2/Phase 3
Completed NCT00395759 - The Visual Effect of an Investigational Artificial Tear in the Tear Layer. N/A
Completed NCT00680108 - A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution Phase 2
Recruiting NCT06064071 - Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD N/A
Completed NCT04139122 - Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease Phase 1/Phase 2
Not yet recruiting NCT06375343 - Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive® Phase 1
Completed NCT01468168 - A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients Phase 2
Completed NCT01014078 - A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease Phase 4
Completed NCT00799682 - Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z® Phase 4
Completed NCT05082974 - Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Laser-assisted in Situ Keratomileusis (LASIK) Phase 3
Recruiting NCT06146881 - Effectiveness of Diquafosol Prophylactic Therapy to Prevent Dry Eye Disease for Cataract Surgery Patients in Indonesia Phase 2
Completed NCT03292809 - CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) Phase 2/Phase 3